

AMENDMENTS TO THE CLAIMS

1.-20. (Canceled)

21. (Original) A method for assessing the immunological potential of a subject said method comprising obtaining a sample from said subject comprising T-cells and subjecting the sample to cell surface discrimination means to determine the presence, absence or level of CD4<sup>+</sup> T-cells selected from the list consisting of:

CMRF-35<sup>++</sup> CD45RO<sup>+</sup>;

CMRF-35<sup>+</sup> CD45RO<sup>+</sup>;

CMRF-35<sup>-</sup> CD45RO<sup>+</sup>;

CMRF-35<sup>+</sup> CD45RO<sup>-</sup>; and

CMRF-35<sup>-</sup> CD45RO<sup>-</sup> T-cells.

22. (Original) The method of Claim 21 wherein the subject is a mammal.

23. (Original) The method of Claim 22 wherein the mammal is a human.

24. (Original) The method of Claim 23 wherein the subject is depleted of or has an increased number of CMRF-35<sup>++</sup> CD45RO<sup>+</sup> T-cells.

25. (Withdrawn) The method of Claim 23 wherein the subject is depleted of or has an increased number of CMRF-35<sup>+</sup> CD45RO<sup>+</sup> T-cells.

26. (Withdrawn) The method of Claim 23 wherein the subject is depleted of or has an increased number of CMRF-35<sup>-</sup> CD45RO<sup>+</sup> T-cells.

27. (Withdrawn) The method of Claim 23 wherein the subject is depleted of or has an increased number of CMRF-35<sup>+</sup> CD45RO<sup>-</sup> T-cells.

28. (Withdrawn) The method of Claim 23 wherein the subject is depleted of or has an increased number of CMRF-35<sup>-</sup> CD45RO<sup>-</sup> T-cells.

29. (Original) The method of Claim 23 wherein the subject has an autoimmune disease.

30. (Original) The method of Claim 29 wherein the autoimmune disease is diabetes.

31. (Original) The method of Claim 23 wherein the subject has an inflammatory condition.

32. (Original) The method of Claim 31 wherein the inflammatory condition is psoriasis.

**Application No.:** 10/577,627  
**Filing Date:** April 28, 2006

33. **(Original)** The method of Claim 31 wherein the inflammatory condition is arthritis.

34.-36. **(Canceled)**

37. **(Previously presented)** The method of claim 21, wherein said CD4<sup>+</sup> T cells are CMRF-35<sup>++</sup> CD45RO<sup>+</sup> CXCR3<sup>+</sup> T cells.